Ibuprofen is a drug that’s commonly used to treat things like headaches and muscular pain, but new research shows that it could also be effective in preventing Alzheimer’s disease. Publishing their findings in the Journal of Alzheimer's Disease, the research team, led by Dr. Patrick McGeer, CEO of Aurin Biotech in Canada, said ibuprofen could prevent the development of Alzheimer’s in individuals with high levels of Abeta 42. Abeta 42 is a peptide that’s present in saliva which people who are at risk of Alzheimer’s have higher levels of. Because Abeta 42 triggers an inflammatory response, the researchers say ibuprofen, a widely-used nonsteroidal anti-inflammatory drug (NSAID), could be used to halt the process. Furthermore, a simple saliva test would be enough to identify people who are at risk of developing Alzheimer’s. "What we've learned through our research," reports Dr. McGeer, "is that people who are at risk of developing Alzheimer's exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime." Alzheimer's disease is the most common form of dementia, affecting around 5.7 million adults in the United States alone. However, this figure is predicted to rise to almost 14 million by 2050.
A trial involving an anti-inflammatory drug could represent the biggest breakthrough in the treatment of heart attacks and strokes since statins were introduced to help lower cholesterol, its authors say. The study of 10,000 patients found that anti-inflammatory drug canakinumab reduced the risk of a patient who had already had a heart attack having another one in the future. The four-year trial saw patients receive high doses of statins as well as either canakinumab or a placebo. Those who received canakinumab were found to be 15% less likely to suffer from a cardiovascular event than their counterparts who received the placebo. Furthermore, cancer deaths were also halved in patients who received canakinumab. The results, which have been referred to as “exciting” by the British Heart Foundation, are thought to be down to the effect of the anti-inflammatory drug on unchecked inflammation within the heart’s arteries. Presenting their results at the European Society of Cardiology meeting, held in Barcelona, Spain, the research team from Brigham and Women's Hospital in Boston, led by the study's lead author Dr Paul Ridker, said the study represented "a milestone in a long journey". "For the first time, we've been able to definitively show that lowering inflammation independent of cholesterol reduces cardiovascular risk. "This has far-reaching implications." It is thought the trial could now lead to new types of treatment for heart attacks and strokes being developed.